GlyMab Therapeutics

GlyMab Therapeutics is a biotechnology company focused on developing next-generation cancer immunotherapies by targeting tumor-associated carbohydrate antigens (TACAs). The company utilizes a proprietary glyco-engineering platform to create high-affinity monoclonal antibodies and antibody-drug conjugates (ADCs) that specifically recognize glycans such as Globo H and SSEA4, which are prevalent on the surface of various solid tumor cells and cancer stem cells. By focusing on the unique "glyco-code" of cancer, GlyMab aims to provide more precise and effective treatments for difficult-to-treat malignancies, including breast, pancreatic, and lung cancers. Their technology is based on the pioneering research of Dr. Chi-Huey Wong, a world-renowned expert in glycobiology and former President of Academia Sinica. The company is currently advancing its lead candidates through pre-clinical development toward IND-enabling studies.